On fi­nal dash to the clin­ic, Ar­se­nal­Bio hauls in $220M for 'mod­u­lar' cell ther­a­py ap­proach

If Ar­se­nal­Bio does it right, its first CAR-T can­di­date — a po­ten­tial treat­ment for ovar­i­an can­cer — will be in the clin­ic lat­er this year.

And a group of deep-pock­et­ed in­vestors are bet­ting $220 mil­lion that it can.

South San Fran­cis­co-based Ar­se­nal­Bio launched out of the gate in late 2019 amid a wave of ac­tiv­i­ty form­ing around cell ther­a­py 2.0, with promis­es of putting to­geth­er an “ar­se­nal” of tech­nolo­gies that can en­gi­neer cells more pre­cise­ly, in or­der to strike the per­fect bal­ance on ef­fi­ca­cy and safe­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER